Amgen Heats Up Biosimilar Naming Debate; Blasts Calls From Same-Name Advocates

Drug Industry Daily
A A
Hot on the heels of Amgen’s state-level campaign to limit dispensation of biosimilars, the biotech is voicing strong opposition to plans by the FDA to allow biosimilars to share the same international non-proprietary name (INN) as the biologic they reference, calling for unique INNs.

To View This Article:

Login

Subscribe To Drug Industry Daily